Abstract: A physiologically active polypeptide derived from human brain and a DNA fragment comprising the base sequence encoding the polypeptide are disclosed. The polypeptide possesses excellent smooth muscle relaxation activity, diuretic or natriuretic activity, and vasodepressor activity, and is thus useful as a medicine for curing circulation diseases, e.g. cardiac edema, nephric edema, hepatic edema, pulmonary edema, hypertension, congestive heat failure, and acute and chronic renal failure.

Abstract: The gene and cDNA of a procine derived CNP (C-type natriuretic peptide), and a procine derived CNP precursor protein and derivatives thereof are disclosed. The proceine derivative CNP precursor is represented by the following amino acid sequence:Met His Leu Ser Gln Leu Leu Ala Cys Ala - Leu Leu Leu Thr Leu Leu Ser Leu Arg Pro - Ser Glu Ala Lys Pro Gly Ala Pro Pro Lys - Val Pro Arg Thr Pro Pro Gly Glu Glu Val - Ala Glu Pro Gln Ala Ala Gly Gly Gly Gln - Lys Lys Gly Asp Lys Thr Pro Gly Gly Gly - Gly Ala Asn Leu Lys Gly Asp Arg Ser Arg - Leu Leu Arg Asp Leu Arg Val Asp Thr Lys - Ser Arg Ala Ala Trp Ala Arg Leu Leu His - Glu His Pro Asn Ala Arg Lys Tyr Lys Gly - Gly Asn Lys Lys Gly Leu Ser Lys Gly Cys - Phe Gly Leu Lys Leu Asp Arg Ile Gly SerThese derivatives are novel and have natriuretic and hypotensive activities.

Abstract: A cDNA coding for a rat derived CNP (rCNP: C-type natriuretic pepteide), and a rat derived CNP precursor protein and derivatives thereof are disclosed.The rat derived CNP precursor is represented by the following amino acid sequence.Met His Leu Ser Gln Leu Ile Ala Cys Ala Leu Leu Leu Ala Leu Leu Ser Leu Arg Pro Ser Glu Ala Lys Pro Gly Thr Pro Pro Lys Val Pro Arg Thr Pro Pro Gly Glu Glu Leu Ala Glu Pro Gln Ala Ala Gly Gly Asn Gln Lys Lys Gly Asp Lys Thr Pro Gly Gly Gly Gly Ala Asn Leu Lys Gly Asp Arg Ser Arg Leu Leu Arg Asp Leu Arg Val Asp Thr Lys Ser Arg Ala Ala Trp Ala Arg Leu Leu His Glu His Pro Asn Ala Arg Lys Tyr Lys Gly Gly Asn Lys Lys Gly Leu Ser Lys Gly Cys Phe Gly Leu Lys Leu Asp Arg Ile Gly Ser Met Ser Gly Leu Gly CysThe rCNP precursor and its derivatives are novel and have natriuretic and hypotensive activities.

Abstract: Adrenomedullin which is a novel peptide having a hypotensive effect; proadrenomedullin N-terminal 20 peptide (proAM-N20) corresponding to an amino acid sequence of an N-terminus of proadrenomedullin, having a catecholamine secretion inhibitory effect; proadrenomedullin N-terminal 10-20 peptide (proAM-N(10-20)) having a Na channel inhibitory effect, and a gene encoding these peptides are provided. In addition, according to the present invention, these peptides in a sample containing adrenomdullin or proAM-N20 in an unknown amount can be quantified by using an antibody against adrenomedullin, proAM-N20, or its fragment.

Abstract: According to the present invention, adrenomedullin which is a novel peptide having a hypotensive effect; proadrenomedullin N-terminal 20 peptide (proAM-N20) corresponding to an amino acid sequence of an N-terminus of proadrenomedullin, having a catecholamine secretion inhibitory effect; proadrenomedullin N-terminal 10-20 peptide (proAM-N(10-20)) having a Na channel inhibitory effect, and a gene encoding these peptides are provided. In addition, according to the present invention, these peptides in a sample containing adrenomdullin or proAM-N20 in an unknown amount can be quantified by using an antibody against adrenomedullin, proAM-N20, or its fragment.

Abstract: According to the present invention, adrenomedullin which is a novel peptide having a hypotensive effect; proadrenomedullin N-terminal 20 peptide (proAM-N20) corresponding to an amino acid sequence of an N-terminus of proadrenomedullin, having a catecholamine secretion inhibitory effect; proadrenomedullin N-terminal 10-20 peptide (proAM-N(10-20)) having a Na channel inhibitory effect, and a gene encoding these peptides are provided. In addition, according to the present invention, these peptides in a sample containing adrenomdullin or proAM-N20 in an unknown amount can be quantified by using an antibody against adrenomedullin, proAM-N20, or its fragment.

Abstract: According to the present invention, adrenomedullin which is a novel peptide having a hypotensive effect; proadrenomedullin N-terminal 20 peptide (proAM-N20) corresponding to an amino acid sequence of an N-terminus of proadrenomedullin, having a catecholamine secretion inhibitory effect; proadrenomedullin N-terminal 10-20 peptide (proAM-N(10-20)) having a Na channel inhibitory effect, and a gene encoding these peptides are provided. In addition, according to the present invention, these peptides in a sample containing adrenomedullin or proAM-N20 in an unknown amount can be quantified by using an antibody against adrenomedullin, proAM-N20, or its fragment.

Abstract: There are disclosed a new peptide .alpha.-hANP of the following structure: ##STR1## and acid addition salt thereof; a diuretic composition and a hypotensor composition containing the .alpha.-hANP or an acid addition salt thereof; and processes for the production thereof.

Abstract: A peptide composed of 53 amino acid residues represented by the following amino acid sequence: (see SEQ ID NO: 1) ##STR1## and derivatives thereof represented by the following amino acid sequence: (see SEQ ID NO: 2) ##STR2## wherein X is as shown in the specification, are disclosed. These polypeptides are novel and have natriuretic and hypotensive actions.

Abstract: A novel peptide that exhibits a natriuretic action and a vasodepressor activity, and hence, that is applicable as a diagnostic reagent. The novel peptide is manufactured by the procedure of genetic engineering as well as by the methods of purification from chicken brains or by chemical synthesis.

Abstract: A novel peptide that exhibits a natriuretic action and a vasodepressor activity, and hence, that is applicable for a diagnostic reagent. The novel peptide is manufactured by tile procedure of genetic engineering as well as by the methods of purification from frog brains or by chemical synthesis.

Abstract: Disclosed is a DNA fragment comprising a base sequence coding for a peptide occurring in human atrium cordis and having diuretic action or a precursor of the peptide, plasmids containing the DNA fragment, microorganisms transformed with the plasmid, and a process for production of the peptide using the transformant.Also disclosed is a new peptide consisting of 126 amino acids occurring in human atrium cordis and a precursor thereof. The peptide has notable diuretic action and hypotensive or antihypertensive actions.

Abstract: Disclosed herein is a physiologically-active peptide represented by the following general formula (I): ##STR1## wherein X means H or H-Asp-Ser-Gly- and Y denotes -Asn-Val-Leu-Arg-Arg-Tyr-OH, -Asn-Val-Leu-Arg-Arg-OH, -Asn-Val-Leu-Arg-Tyr-OH, -Asn-Val-Leu-Arg-OH, -Asn-Val-Leu-OH or -Asn-Ser-Phe-Arg-Tyr-OH, or a salt thereof.

Abstract: There are disclosed a new peptide .alpha.-hANP of the following structure: ##STR1## and acid addition salt thereof; a diuretic composition and a hypotensor composition containing the .alpha.-hANP or an acid addition salt thereof; and processes for the production thereof.

Abstract: There are disclosed a new peptide .beta.-rANP of the following structure: ##STR1## and acid addition salt thereof; a diuretic composition and a hypotensor composition containing the .beta.-rANP or an acid addition salt thereof; and processes for the production thereof.

Abstract: There are disclosed a new peptide .beta.-hANP of the following structure: ##STR1## and acid addition salt thereof; a diuretic composition and a hypotensor composition containing a .beta.-hANP or an acid addition salt thereof; and processes for the production thereof.